Groningen, the Netherlands, Aug 12, 2013 – Biotechnology company Mucosis B.V. today announced the publication in the peer-reviewed journal PLOS ONE of preclinical data showing that its innovative SynGEM® is safe and protective in animal models. According to the report, SynGEM®, a vaccine based on the Mimopath® vaccine technology allows presentation of a stable prefusion-like trimeric F protein, a feature considered important for the induction of functional immunity. Intranasally administrated SynGEM® induced locally secreted IgA in the mucosal layers in addition to robust levels of systemic virus neutralizing antibodies both in mice and cotton rats. (more…)
Author: Willem van Lawick
-
Prosensa Awarded EUR 6 million EU FP7 Research Grant
LEIDEN, The Netherlands – August 1, 2013 – Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it has been awarded a prestigious Framework Programme 7 (FP7) research grant from the European Union to support the ongoing clinical study of the Company’s third novel development candidate, PRO045, for the treatment of Duchenne muscular dystrophy (DMD). The project, titled “Consortium for Products Across Europe in Duchenne Muscular Dystrophy” (SCOPE-DMD) is expected to run for three years. Prosensa is part of a high-quality, pan-European consortium that has been awarded the grant of approximately EUR 6 million to evaluate its exon 45-skipping drug candidate, PRO045, in an innovatively designed clinical proof-of-concept study in boys with DMD. (more…)
-
Kiadis Pharma to receive GMP manufacturing license and GMP certificate
Amsterdam, The Netherlands, July 23, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that its Quality Control (QC) laboratory and the associated Quality system has been inspected for good-manufacturing-practice (GMP) by the Dutch Health Care Inspectorate (IGZ) and has fully met the EU GMP standards. As a result, Kiadis Pharma will receive a GMP manufacturing license and GMP certificate for its QC laboratory from the Dutch Ministry of Health, Welfare and Sport. (more…)
-
Prosensa Holding N.V. announces closing of Initial Public Offering
Leiden, the Netherlands—July 8, 2013—Prosensa Holding N.V. (“Prosensa”) announced today the closing of its previously announced initial public offering of 6,900,000 of its ordinary shares at a price of $13.00 per share (including an additional 900,000 ordinary shares pursuant to the exercise of the over-allotment option by the underwriters). The ordinary shares began trading on the Nasdaq Global Market on June 28, 2013 under the symbol “RNA”. (more…)
-
Prosensa Holding B.V. prices Initial Public Offering
Leiden, the Netherlands—June 27, 2013—Prosensa Holding B.V. (“Prosensa”) announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $13.00 per share, before underwriting discounts. Prosensa has also granted the underwriters a 30-day option to purchase up to an additional 900,000 ordinary shares to cover over-allotments, if any. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on June 28, 2013 under the symbol “RNA.”